Background:LY01005(Goserelin acetate sustained-release microsphere injection)is a modified gonadotropin-releasing hormone(GnRH)agonist injected monthly.This phase III trial study aimed to evaluated the efficacy and sa...Background:LY01005(Goserelin acetate sustained-release microsphere injection)is a modified gonadotropin-releasing hormone(GnRH)agonist injected monthly.This phase III trial study aimed to evaluated the efficacy and safety of LY01005 in Chinese patients with prostate cancer.Methods:We conducted a randomized controlled,open-label,non-inferiority trial across 49 sites in China.This study included 290 patients with prostate cancer who received either LY01005 or goserelin implants every 28 days for three injections.The primary efficacy endpoints were the percentage of patients with testosterone suppression≤50 ng/dL at day 29 and the cumulative probability of testosterone≤50 ng/dL from day 29 to 85.Non-inferiority was prespecified at a margin of-10%.Secondary endpoints included significant castration(≤20 ng/dL),testosterone surge within 72 h following repeated dosing,and changes in luteinizing hormone,follicle-stimulating hormone,and prostate specific antigen levels.Results:On day 29,in the LY01005 and goserelin implant groups,testosterone concentrations fell below medical-castration levels in 99.3%(142/143)and 100%(140/140)of patients,respectively,with a difference of-0.7%(95%confidence interval[CI],-3.9%to 2.0%)between the two groups.The cumulative probabilities of maintaining castration from days 29 to 85 were 99.3%and 97.8%,respectively,with a between-group difference of 1.5%(95%CI,-1.3%to 4.4%).Both results met the criterion for non-inferiority.Secondary endpoints were similar between groups.Both treatments were well-tolerated.LY01005 was associated with fewer injection-site reactions than the goserelin implant(0%vs.1.4%[2/145]).Conclusion:LY01005 is as effective as goserelin implants in reducing testosterone to castration levels,with a similar safety profile.Trial registration:ClinicalTrials.gov,NCT04563936.展开更多
All-solid-state lithium batteries(ASSLBs)are promising for safety and high-energy-density large-scale energy storage.In this contribution,we propose a Li_(3–4x)Zr_(x)PS_(4)(LZPS)by Zr-dopedβ-Li_(3)PS_(4)(LPS)as a no...All-solid-state lithium batteries(ASSLBs)are promising for safety and high-energy-density large-scale energy storage.In this contribution,we propose a Li_(3–4x)Zr_(x)PS_(4)(LZPS)by Zr-dopedβ-Li_(3)PS_(4)(LPS)as a novel solid electrolyte(SE)for ASSLBs based on experimental and simulation methods.The structure,electronic property,mechanical property,and ionic transport properties of LZPS(x=0,0.03,0.06,and 0.1)are investigated with first-principles calculations.Meanwhile,LZPS is prepared by solid states reaction method.By combining experimental analysis and first-principles calculations,it is confirmed that a small amount of Zr4+can be successfully doped into the framework ofβ-LPS composites without significantly compromising structural integrity.When the Zr^(4+)concentration is x=0.03,the doped material Li_(2.88)Zr_(0.03)PS_(4)exhibits the highest ionic conductivity(5.1×10^(−4)S·cm^(−1))at 30℃,and the Li-ion migration energy barrier is the lowest.The Li_(2.88)Zr_(0.03)PS_(4)SE has obtained the best mechanical properties,the good ductility,and shear deformation resistance,which can better maintain the structural stability of the battery.In addition,the Li/Li symmetrical cell is assembled,which shows excellent electrochemical stability of electrolyte against lithium.The constructed all-solid-state batteries(LiCoO_(2)-Li_(6)PS_(5)Cl|Li_(2.88)Zr_(0.03)PS_(4)|Li-In)delivers an initial discharge capacity of 130.4 mAh·g^(−1)at 0.2 C and a capacity retention of 85.1%after 100 cycles at room temperature.This study provides a promising electrolyte for the application of ASSLBs with high ionic conductivity and excellent stability against lithium.展开更多
文摘Background:LY01005(Goserelin acetate sustained-release microsphere injection)is a modified gonadotropin-releasing hormone(GnRH)agonist injected monthly.This phase III trial study aimed to evaluated the efficacy and safety of LY01005 in Chinese patients with prostate cancer.Methods:We conducted a randomized controlled,open-label,non-inferiority trial across 49 sites in China.This study included 290 patients with prostate cancer who received either LY01005 or goserelin implants every 28 days for three injections.The primary efficacy endpoints were the percentage of patients with testosterone suppression≤50 ng/dL at day 29 and the cumulative probability of testosterone≤50 ng/dL from day 29 to 85.Non-inferiority was prespecified at a margin of-10%.Secondary endpoints included significant castration(≤20 ng/dL),testosterone surge within 72 h following repeated dosing,and changes in luteinizing hormone,follicle-stimulating hormone,and prostate specific antigen levels.Results:On day 29,in the LY01005 and goserelin implant groups,testosterone concentrations fell below medical-castration levels in 99.3%(142/143)and 100%(140/140)of patients,respectively,with a difference of-0.7%(95%confidence interval[CI],-3.9%to 2.0%)between the two groups.The cumulative probabilities of maintaining castration from days 29 to 85 were 99.3%and 97.8%,respectively,with a between-group difference of 1.5%(95%CI,-1.3%to 4.4%).Both results met the criterion for non-inferiority.Secondary endpoints were similar between groups.Both treatments were well-tolerated.LY01005 was associated with fewer injection-site reactions than the goserelin implant(0%vs.1.4%[2/145]).Conclusion:LY01005 is as effective as goserelin implants in reducing testosterone to castration levels,with a similar safety profile.Trial registration:ClinicalTrials.gov,NCT04563936.
基金supported by the National Natural Science Foundation of China(No.11902144).
文摘All-solid-state lithium batteries(ASSLBs)are promising for safety and high-energy-density large-scale energy storage.In this contribution,we propose a Li_(3–4x)Zr_(x)PS_(4)(LZPS)by Zr-dopedβ-Li_(3)PS_(4)(LPS)as a novel solid electrolyte(SE)for ASSLBs based on experimental and simulation methods.The structure,electronic property,mechanical property,and ionic transport properties of LZPS(x=0,0.03,0.06,and 0.1)are investigated with first-principles calculations.Meanwhile,LZPS is prepared by solid states reaction method.By combining experimental analysis and first-principles calculations,it is confirmed that a small amount of Zr4+can be successfully doped into the framework ofβ-LPS composites without significantly compromising structural integrity.When the Zr^(4+)concentration is x=0.03,the doped material Li_(2.88)Zr_(0.03)PS_(4)exhibits the highest ionic conductivity(5.1×10^(−4)S·cm^(−1))at 30℃,and the Li-ion migration energy barrier is the lowest.The Li_(2.88)Zr_(0.03)PS_(4)SE has obtained the best mechanical properties,the good ductility,and shear deformation resistance,which can better maintain the structural stability of the battery.In addition,the Li/Li symmetrical cell is assembled,which shows excellent electrochemical stability of electrolyte against lithium.The constructed all-solid-state batteries(LiCoO_(2)-Li_(6)PS_(5)Cl|Li_(2.88)Zr_(0.03)PS_(4)|Li-In)delivers an initial discharge capacity of 130.4 mAh·g^(−1)at 0.2 C and a capacity retention of 85.1%after 100 cycles at room temperature.This study provides a promising electrolyte for the application of ASSLBs with high ionic conductivity and excellent stability against lithium.
